Showing 1 to 2 of 2 results


FDA Director Prasad Resigns, Then Returns Amidst Controversy
Vinay Prasad, the FDA's Center for Biologics Evaluation and Research director, resigned on July 30th following criticism of the agency's handling of a gene therapy linked to patient deaths and attacks from Laura Loomer, but returned to his position on August 10th at the FDA's request.
FDA Director Prasad Resigns, Then Returns Amidst Controversy
Vinay Prasad, the FDA's Center for Biologics Evaluation and Research director, resigned on July 30th following criticism of the agency's handling of a gene therapy linked to patient deaths and attacks from Laura Loomer, but returned to his position on August 10th at the FDA's request.
Progress
40% Bias Score

Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.

Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.
Progress
44% Bias Score
Showing 1 to 2 of 2 results